PLEOMORPHIC RHABDOMYOSARCOMA
Clinical trials for PLEOMORPHIC RHABDOMYOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new PLEOMORPHIC RHABDOMYOSARCOMA trials appear
Sign up with your email to follow new studies for PLEOMORPHIC RHABDOMYOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink sarcomas
Disease control Recruiting nowThis early-stage trial tests whether giving a targeted drug (palbociclib) before immunotherapy (pembrolizumab) is safe and can help shrink tumors in people with certain soft tissue sarcomas. About 8 participants will receive the combination. The main goal is to check for side eff…
Matched conditions: PLEOMORPHIC RHABDOMYOSARCOMA
Phase: PHASE1 • Sponsor: John Rieth • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Proton beam boost: new hope for inoperable sarcomas?
Disease control Recruiting nowThis study tests whether a higher dose of proton radiation can better control inoperable soft tissue sarcomas without increasing side effects. Forty adults with these rare tumors will receive targeted radiation over 4 weeks. Researchers will also look at blood and imaging markers…
Matched conditions: PLEOMORPHIC RHABDOMYOSARCOMA
Phase: PHASE2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New 3-Week radiation plan aims to cut side effects for sarcoma patients
Disease control Recruiting nowThis study tests whether a personalized 3-week course of proton radiation before surgery for soft tissue sarcoma can reduce long-term side effects compared to standard X-ray radiation. About 110 adults in Norway will receive either proton or X-ray therapy, chosen individually for…
Matched conditions: PLEOMORPHIC RHABDOMYOSARCOMA
Phase: PHASE2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for sarcoma patients: immunotherapy plus chemo shows promise
Disease control Recruiting nowThis study tests a new combination of drugs (tislelizumab, liposomal doxorubicin, and ifosfamide) as a first treatment for people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread. The goal is to see if this combo shrinks tumors and is safe. About …
Matched conditions: PLEOMORPHIC RHABDOMYOSARCOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC